LIB Therapeutics Looks Competitive With Big Pharma in Hypercholesterolemia

 
• By Elizabeth Cairns

Phase III results with lerodalcibep are in the same ballpark as heavy-hitting established PCSK9 inhibiting drugs.

Cholesterol plaque in artery

More from Clinical Trials

More from R&D